Building a blueprint to manipulate the immune system

Why do some vaccines protect for a lifetime, while threats like tumors and viruses present such an ongoing challenge? The answer lies in the immune system's memory and how invading pathogens hack the system.

New therapeutic target expands options for multiple myeloma

In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, ...

page 12 from 38